The nucleus-encoded 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) regulates cyclophilin D (cypD) in the mitochondrial matrix. CypD regulates opening of mitochondrial permeability transition pores. Both mechanisms may be affected by amyloid β peptides accumulated in mitochondria in Alzheimer's disease (AD). In order to clarify changes occurring in brain mitochondria, we evaluated interactions of both mitochondrial proteins in vitro (by surface plasmon resonance biosensor) and detected levels of various complexes of 17β-HSD10 formed in vivo (by sandwich ELISA) in brain mitochondria isolated from the transgenic animal model of AD (homozygous McGill-R-Thy1-APP rats) and in cerebrospinal fluid samples of AD patients. By surface plasmon resonance biosensor, we observed the interaction of 17β-HSD10 and cypD in a direct real-time manner and determined, for the first time, the kinetic parameters of the interaction (ka 2.0 × 105 M1s-1, kd 5.8 × 104 s-1, and KD 3.5 × 10-10 M). In McGill-R-Thy1-APP rats compared to controls, levels of 17β-HSD10-cypD complexes were decreased and those of total amyloid β increased. Moreover, the levels of 17β-HSD10-cypD complexes were decreased in cerebrospinal fluid of individuals with AD (in mild cognitive impairment as well as dementia stages) or with Frontotemporal lobar degeneration (FTLD) compared to cognitively normal controls (the sensitivity of the complexes to AD dementia was 92.9%, that to FTLD 73.8%, the specificity to AD dementia equaled 91.7% in a comparison with the controls but only 26.2% with FTLD). Our results demonstrate the weakened ability of 17β-HSD10 to regulate cypD in the mitochondrial matrix probably via direct effects of amyloid β. Levels of 17β-HSD10-cypD complexes in cerebrospinal fluid seem to be the very sensitive indicator of mitochondrial dysfunction observed in neurodegeneration but unfortunately not specific to AD pathology. We do not recommend it as the new biomarker of AD.

Department of Neurology Memory Disorders Clinic 2nd Faculty of Medicine Charles University Prague and Motol University Hospital 5 uvalu 84 150 06 Prague 5 Czech Republic

Institute of Computer Science Czech Academy of Sciences Pod vodarenskou vezi 271 2 182 07 Prague Czech Republic

Institute of Photonics and Electronics of the Czech Academy of Sciences Chaberska 57 182 51 Prague Czech Republic

Institute of Physiology of the Czech Academy of Sciences Videnska 1083 142 20 Prague Czech Republic

National Institute of Mental Health Topolova 748 250 67 Klecany Czech Republic

Zobrazit více v PubMed

Yang SY, He XY, Schulz H. Multiple functions of type 10 17β-hydroxysteroid dehydrogenase. Trends Endocrin Met. 2005;16:167–175. doi: 10.1016/j.tem.2005.03.006. PubMed DOI

Yang SY, He XY, Isaacs C, Dobkin C, Miller D, Philipp M. Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders. J Steroid Biochem Mol Biol. 2014;143:460–472. doi: 10.1016/j.jsbmb.2014.07.001. PubMed DOI

Rauschenberger K, Schöler K, Sass JO, Sauer S, Djuric Z, Rumig C, Wolf NI, Okun JG, Kolker S, Schwarz H, Fisher C, Grziwa B, Runz H, Numann A, Shafqat N, Kavanagh KL, Hammerling G, Wanders RJA, Shield JPH, Wendel U, Stern D, Nawroth P, Hoffmann GF, Bartram CR, Arnold B, Bierhaus A, Oppermann U, Steinbeisser H, Zschocke J. A non-enzymatic function of 17β-hydroxysteroid dehydrogenase type 10 is required for mitochondrial integrity and cell survival. EMBO Mol Med. 2010;2:51–62. doi: 10.1002/emmm.200900055. PubMed DOI PMC

Harbauer AB, Zahedi RP, Sickman A, Pfanner N, Meisinger C. The protein import machinery of mitochondria—a regulatory hub in metabolism, stress, and disease. Cell Metab. 2014;19:357–372. doi: 10.1016/j.cmet.2014.01.010. PubMed DOI

Bertolin G, Jacoupy M, Traver S, Ferrendo-Miguel R, Saint Georges T, Grenier K, Ardila-Osorio H, Muriel MP, Takahashi H, Lees AJ, Gautier C, Guedin D, Coge F, Fon EA, Brice A, Corti O. Parkin maintains mitochondrial levels of the protective Parkinson's disease-related enzyme 17-β hydroxysteroid dehydrogenase type 10. Cell Death Differ. 2015;22:1563–1576. doi: 10.1038/cdd.2014.224. PubMed DOI PMC

Von Stockum S, Nardin A, Schrepfer E, Ziviani E. Mitochondrial dynamics and mitophagy in Parkinson's disease: a fly point of view. Neurobiol Dis. 2016;90:58–67. doi: 10.1016/j.nbd.2015.11.002. PubMed DOI

Yan SD, Stern DM. Mitochondrial dysfunction and Alzheimer's disease: role of amyloid-β peptide alcohol dehydrogenase (ABAD) Int J Exp Path. 2005;86:161–171. doi: 10.1111/j.0959-9673.2005.00427.x. PubMed DOI PMC

Yan SD, Fu J, Soto C, Chen X, Zhu H, Al-Mohanna F, Collison K, Zhu A, Stern E, Saido T, Tohyama M, Ogawa S, Roher A, Stern D. An intracellular protein that binds amyloid-beta peptide and mediates neurotoxicity in Alzheimer's disease. Nature. 1997;389:689–695. doi: 10.1038/39522. PubMed DOI

Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Casperson C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier Z, Arancio O, Stern D. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science. 2004;304:448–452. doi: 10.1126/science.1091230. PubMed DOI

Kristofikova Z, Bockova M, Hegnerova K, Bartos A, Klaschka J, Ricny J, Ripova D, Homola J. Enhanced levels of mitochondrial enzyme 17β-hydroxysteroid dehydrogenase type 10 in patients with Alzheimer disease and multiple sclerosis. Mol Biosyst. 2009;5:1174–1179. doi: 10.1039/b904799a. PubMed DOI

Kristofikova Z, Ripova D, Bartos A, Bockova M, Hegnerova K, Ricny J, Cechova L, Vrajov M, Homola J. Neuroinflammation and complexes of 17β-hydroxysteroid dehydrogenase type 10—amyloid β in Alzheimer's disease. Curr Alzheimer Res. 2013;10:165–173. doi: 10.2174/1567205011310020006. PubMed DOI

Kristofikova Z, Ricny J, Vyhnalek M, Hort J, Laczo J, Sirova J, Klaschka J, Ripova D. Levels of 17β-hydroxysteroid dehydrogenase type 10 in cerebrospinal fluid of people with mild cognitive impairment and various types of dementias. J Alzheimers Dis. 2015;48:105–114. doi: 10.3233/JAD-142898. PubMed DOI

Oppermann UCD, Salim S, Tjernberg LO, Terenius L, .Jörnvall H. Binding of amyloid β-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme acitivity with implications for apoptosis in Alzheimer's disease. FEBS Lett. 1999;451:238–242. doi: 10.1016/S0014-5793(99)00586-4. PubMed DOI

Powell AJ, Read JA, Banfield MJ, Gunn-Moore F, Yan SD, Lusbader J, Stern AR, Stern DM, Brady RL. Recognition of structurally diverse substrates by type II 3-hydroxyacyl-CoA dehydrogenase (HADH II)/amyloid-β binding alcohol dehydrogenase (ABAD) J Mol Biol. 2000;303:311–327. doi: 10.1006/jmbi.2000.4139. PubMed DOI

Yan Y, Liu Y, Sorci M, Belfort G, Lustbader JW, Yan SD, Wang C. Surface plasmon resonance and nuclear magnetic resonance studies of ABAD—Aβ interactions. Biochemistry. 2007;46:1724–1731. doi: 10.1021/bi061314n. PubMed DOI

Hegnerova K, Bockova M, Vaisocherova H, Kristofikova Z, Ricny J, Ripova D, Homola J. Surface plasmon resonance biosensors for detection of Alzheimer disease biomarker. Sens Actuator B Chem. 2009;139:69–73. doi: 10.1016/j.snb.2008.09.006. DOI

Chen JX, Yan SD. Role of mitochondrial amyloid-β in Alzheimer's disease. J Alzheimers Dis. 2010;20:S569–S578. doi: 10.3233/JAD-2010-100357. PubMed DOI

Muirhead KEA, Borger E, Aitken L, Conway SJ, Gunn-Moore FJ. The consequences of mitochondrial amyloid β-peptide in Alzheimer's disease. Biochem J. 2010;426:255–270. doi: 10.1042/BJ20091941. PubMed DOI

Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, Guo L, Chen D, Stern DM, Gunn-Moore FJ, Chen JX, Arancio O, Yan SD. Inhibition of amyloid-β (Aβ) peptide-binding alcohol dehydrogenase-Aβ interaction reduces Aβ accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J Neurosci. 2011;31:2313–2320. doi: 10.1523/JNEUROSCI.4717-10.2011. PubMed DOI PMC

Carlson EA, Marquez RT, Du F, Wang Y, Xu L, Yan SD. Overexpression of 17β-hydroxysteroid dehydrogenase type 10 increases pheochromocytoma cell growth and resistance to cell death. BMC Cancer. 2015;15:166. doi: 10.1186/s12885-015-1173-5. PubMed DOI PMC

Du H, Yan SD. Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta. Biochim Biophys Acta. 2010;1802:198–204. doi: 10.1016/j.bbadis.2009.07.005. PubMed DOI PMC

Du H, Guo L, Zhang W, Rydzewska M, Yan SD. Cyclophilin D deficiency improves mitochodnrial function and learning/memory in aging Alzheimer disease mouse model. Neurobiol Aging. 2011;32:398–406. doi: 10.1016/j.neurobiolaging.2009.03.003. PubMed DOI PMC

Springer T, Piliarik M, Homola J. Surface plasmon resonance sensor with dispersionless microfluidics for direct detection of nucleic acids at the low femtomole level. Sensor Actuat B Chem. 2010;145:588–591. doi: 10.1016/j.snb.2009.11.018. DOI

Springer T, Piliarik M, Homola J. Real-time monitoring of biomolecular interactions in blood plasma using a surface plasmon resonance biosensor. Anal Bioanal Chem. 2010;398:1955–1961. doi: 10.1007/s00216-010-4159-9. PubMed DOI

Springer T, Homola J. Biofunctionalized gold nanoparticles for SPR-biosensor-based detection of CEA in blood plasma. Anal Bioanal Chem. 2012;404:2869–2875. doi: 10.1007/s00216-012-6308-9. PubMed DOI

Kissinger CR, Rejto PA, Pelletier LA, Thomson JA, Showalter RE, Abre MA, Agree CS, Margosiak S, Meng JJ, Aust TM, Vanderpool D, Li B, Tempczyk-Russell A, Villafranca JE. Crystal structure of human ABAD/HSD10 with a bound inhibitor: implications for design of Alzheimer's disease therapeutics. J Mol Biol. 2004;342:943–952. doi: 10.1016/j.jmb.2004.07.071. PubMed DOI

Rajapakse N, Shimizu K, Payne M, Busija D. Isolation and characterization of intact mitochondria from neonatal rat brain. Brain Res Protoc. 2001;8:176–183. doi: 10.1016/S1385-299X(01)00108-8. PubMed DOI

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254. doi: 10.1016/0003-2697(76)90527-3. PubMed DOI

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer´s Association workgroups on diagnostic guidelines for Alzheimer's diseases. Alzheimers Dement. 2011;7:270–279. doi: 10.1016/j.jalz.2011.03.008. PubMed DOI PMC

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–269. doi: 10.1016/j.jalz.2011.03.005. PubMed DOI PMC

Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–1554. doi: 10.1212/WNL.51.6.1546. PubMed DOI

Sheskin DJ. Measures of association/correlation. In: Sheskin DJ, editor. Handbook of parametric and nonparametric statistical procedures. New York: Chapman and Hall/CRC; 2011. pp. 1219–1413.

Luvisetto S, Basso E, Petronilli V, Bernardi P, Forte M. Enhancement of anxiety, facilitation of avoidance behavior, and occurrence of adult-onset obesity in mice lacking mitochondrial cyclophilin D. Neuroscience. 2008;155:585–596. doi: 10.1016/j.neuroscience.2008.06.030. PubMed DOI PMC

Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis. 2010;20:113–126. doi: 10.3233/JAD-2010-1349. PubMed DOI

Petrasek T, Vojtechova I, Lobellova V, Popelikova A, Janikova M, Brozka H, Houdek P, Sladek M, Sumova A, Kristofikova Z, Vales K, Stuchlik A. The McGill transgenic rat model of Alzheimer's disease displays cognitive and motor impairments, changes in anxiety and social behavior, and altered circadian activity. Front Aging Neurosci. 2018;10:250. doi: 10.3389/fnagi.2018.00250. PubMed DOI PMC

Iulita MF, Allard S, Richter L, Munter LM, Ducatenzeiler A, Weise C, Do Carmo S, Klein WL, Multhaup G, Cuello AC. Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathol Commum. 2014;2:61. doi: 10.1186/2051-5960-2-61. PubMed DOI PMC

Nilsen LH, Witter MP, Sonnewald U. Neuronal and astrocytic metabolism in a transgenic rat model of Alzheimer's disease. J Cereb Blood Flow Metab. 2014;34:906–914. doi: 10.1038/jcbfm.2014.37. PubMed DOI PMC

Martino Adami PV, Quijano C, Magnani N, Galeano P, Evelson P, Cassina A, Do Carmo S, Leal MC, Castano EM, Cuello AC, Morelli L. Synaptosomal bioenergetic defects are associated with cognitive impairment in a transgenic rat model of early Alzheimer's disease. J Cereb Blood Flow Metab. 2017;37:69–84. doi: 10.1177/0271678X15615132. PubMed DOI PMC

Reddy PH, Beal F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med. 2008;14:45–53. doi: 10.1016/j.molmed.2007.12.002. PubMed DOI PMC

Hemmerova E, Springer T, Kristofikova Z, Homola J. In vitro study of interaction of 17β-hydroxysteroid dehydrogenase type 10 and cyclophilin D and its potential implications for Alzheimer's disease. Sci Rep. 2019;9:16700. doi: 10.1038/s41598-019-53157-7. PubMed DOI PMC

Rossi L, Lombardo MF, Ciriolo MR, Rotilio G. Mitochondrial dysfunction in neurodegenerative diseases associated with copper imbalance. Neurochem Res. 2004;29:493–504. doi: 10.1023/B:NERE.0000014820.99232.8a. PubMed DOI

Kristofikova Z, Ricny J, Kolarova M, Vyhnalek M, Hort J, Lacso J, Sirova J, Ripova D. Interactions between amyloid β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2014;42(3):S91–S98. doi: 10.3233/JAD-132393. PubMed DOI

Ionic Environment Affects Biomolecular Interactions of Amyloid-β: SPR Biosensor Study

Study of Biomolecular Interactions of Mitochondrial Proteins Related to Alzheimer's Disease: Toward Multi-Interaction Biomolecular Processes